|Comparing the Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel Syndrome Severity and Quality of Life: A Double-blind Randomized Clinical Trial|
|Khadijeh Hatami1, Amir-Hooman Kazemi-Motlagh1, Hossein Ajdarkosh2, Arman Zargaran3, Mehrdad Karimi1, Ahmad Reza Shamshiri4, Mohammad Reza Ghadir5|
|1Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
2Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran
3Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Community Oral Health Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
5Gastroenterology and Hepatology Research Center, Qom University of Medical Sciences, Qom, Iran
CJMB 2020; 7: 186-194
Viewed : 1840 times
Downloaded : 10683 times.
Keywords : Herbal medicine, Irritable bowel syndrome, IBS-severity score, IBS-quality of life
|Full Text(PDF) | Related Articles|
Objectives: The treatment of irritable bowel syndrome (IBS) is not curative and is based on patient symptoms. Some herbal medicines have significant effects on IBS symptoms. The present study aimed to assess the efficacy of a recommended drug from Persian medicine (Cumin Sofouf) on the score of IBS symptom severity and the quality of life as a clinical trial compared with mebeverine, which is a commonly used antispasmodic drug for this disorder.
Materials and Methods: In this double-blind randomized clinical trial, eligible patients were allocated to two groups. One group received 200 mg sustain release mebeverine capsule plus placebo sofouf and another group received the sachets of cumin sofouf plus placebo capsule. Cumin sofouf contains the seed powder of Bunium persicum, Trachyspermum ammi, Foeniculum vulgare, and Pimpinella anisum. Patients were requested to fill IBS-symptom severity score (IBS-SSS) and IBS-quality of life (IBS-QoL) questionnaires at the base and after 4 weeks of treatment.
Results: Data of 40 patients in each group entered the analysis step. Based on the results, IBS-SSS decreased by 120.13 (SD = 66.04) and 70.75 (SD = 50.75) point after 4 weeks in cumin sofouf and mebeverine groups, respectively. in addition, cumin sofouf was statistically more effective than mebeverine, which was also about IBS-SSS substructures. Further, the IBS-QOL score decreased by 17.40 (SD = 13.66) and 8.55 (SD = 6.88) point in sofouf and mebeverine groups, respectively. Finally, cumin sofouf was significantly more effective than mebeverine.
Conclusions: According to the results, cumin sofouf could be recommended as a supplementary remedy for IBS patients.
Cite By, Google Scholar